Ferner Rosalie E
Department of Neurology, Guy's and St. Thomas' Hospitals, Guy's Hospital, London, UK.
Lancet Neurol. 2007 Apr;6(4):340-51. doi: 10.1016/S1474-4422(07)70075-3.
Historically, neurofibromatosis 1 (NF1) has been inextricably linked with neurofibromatosis 2 (NF2). Both are inherited autosomal-dominant neurocutaneous disorders that have high de novo mutation rates and carry a high risk of tumour formation. However, they are clinically and genetically distinct diseases and should be considered as seperate entities. NF1 is a common disease that mainly affects the skin and peripheral nervous system and causes characteristic bony dysplasia. By contrast, NF2 is a rare disorder with a relative paucity of skin manifestations and high-grade malignancy is unusual. Neurological symptoms are the predominant problem and the cardinal sign is bilateral vestibular schwannomas. In this Review, I discuss the pertinent diagnostic, clinical, and genetic symptoms of NF1 and NF2. I also examine the current views on the pathogenesis of these neurocutaneous disorders in the wake of advances in molecular genetics and the development of mouse models of disease.
Lancet Neurol. 2007-4
Neurochirurgie. 1998-11
Rev Neurol Dis. 2009
Radiologe. 2013-12
Annu Rev Pathol. 2007
Med Wieku Rozwoj. 2006
Dermatol Clin. 1995-1
Curr Opin Neurol. 2002-12
Nat Rev Clin Oncol. 2013-8-13
Life (Basel). 2025-2-26
Diagnostics (Basel). 2025-2-17
Front Neurol. 2024-11-29
Indian J Otolaryngol Head Neck Surg. 2024-12
Eye (Lond). 2025-2
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024-10-15
J Neurodev Disord. 2024-8-31